Newsroom

White House bemoans ‘rapidly growing’ drug prices

The White House said Monday that it is “deeply concerned with the rapidly growing prices of specialty and brand name drugs,” a victory for critics of pharmaceutical companies.

Read more

Insurers eye pharma discounts beyond hepatitis C

The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs.

Read more

Obama Health Budget Calls for Authority to Negotiate Drug Prices

The Obama administration’s fiscal 2016 budget request calls for allowing the government to negotiate the price of prescription drugs and giving regulators new funding to fight Ebola.

Read more

Gilead Sciences Earnings: What to Watch

Gilead Sciences Inc. is scheduled to announce its fourth-quarter earnings Feb. 3. Last year, Gilead’s Sovaldi had the top-selling drug launch in history with more than $8.5 billion in sales through the end of September.

Read more